Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amylyx Pharmaceuticals, Inc.AMLX · Entity 259 | Director | June 09, 2022 | June 10, 2022 |
| Atea Pharmaceuticals, Inc.AVIR · Entity 5580 | Director | October 29, 2020 | October 30, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amylyx Pharmaceuticals, Inc.
Report date June 09, 2022 · Filed June 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.56 · Expires 2032-06-09 | Direct | 19,000 |
Reported balance
After 2022-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-09 · Grant · Acquired 19,000 · Balance 19,000 F1: This option shall vest in full upon the earlier of (i) June 9, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in full upon the earlier of (i) June 9, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director.
Atea Pharmaceuticals, Inc.
Report date October 29, 2020 · Filed October 30, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.00 · Expires 2030-10-28 | Direct | 80,000 |
Reported balance
After 2020-10-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-10-29 · Grant · Acquired 80,000 · Balance 80,000 F1: The option vests and becomes exercisable in 36 equal monthly installments following October 29, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in 36 equal monthly installments following October 29, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2022 Filed Jun 10, 2022 20:05 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $13.56 | $0.00 |
DisclosureSEC source: 0000899243-22-021888 · doc4.xml · derivative · entry 1 Cheng Isaac · CIK 0001829696 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 9, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director. Read SEC document |
| January 06, 2022 Filed Jan 11, 2022 01:35 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (Right to Buy) · Derivative | 8,400 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-22-001525 · doc4.xml · derivative · entry 10 Cheng Isaac · CIK 0001829696 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,400 Underlying: Common Stock · 8,400 shares Expires 2032-01-06 F3 · derivative.exercise_date: This option shall vest in full on the date of the Corporation's 2022 Annual Stockholders Meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| January 06, 2022 Filed Jan 11, 2022 01:35 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionSeries C-2 Preferred Stock · Derivative | 1,621,544 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-001525 · doc4.xml · derivative · entry 9 Cheng Isaac · CIK 0001829696 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,621,544 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1 and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1 and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1 and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date. F2 · ownership.nature: These shares are held directly by Morningside Venture Investments Limited, or Morningside, and MVIL, LLC, a wholly-owned subsidiary of Morningside. The Reporting Person is an investment professional at Morningside Technology Advisory, LLC, an indirect advisor to Morningside and MVIL, LLC and may be deemed to indirectly beneficially own the shares held by Morningside and MVIL, LLC. The Reporting Person has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of such shares. Read SEC document |
| January 06, 2022 Filed Jan 11, 2022 01:35 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionSeries C-1 Preferred Stock · Derivative | 974,107 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-001525 · doc4.xml · derivative · entry 8 Cheng Isaac · CIK 0001829696 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 974,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1 and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1 and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1 and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date. F2 · ownership.nature: These shares are held directly by Morningside Venture Investments Limited, or Morningside, and MVIL, LLC, a wholly-owned subsidiary of Morningside. The Reporting Person is an investment professional at Morningside Technology Advisory, LLC, an indirect advisor to Morningside and MVIL, LLC and may be deemed to indirectly beneficially own the shares held by Morningside and MVIL, LLC. The Reporting Person has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of such shares. Read SEC document |
| January 06, 2022 Filed Jan 11, 2022 01:35 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionSeries B Preferred Stock · Derivative | 6,410,964 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-001525 · doc4.xml · derivative · entry 7 Cheng Isaac · CIK 0001829696 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 6,410,964 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1 and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1 and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1 and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date. F2 · ownership.nature: These shares are held directly by Morningside Venture Investments Limited, or Morningside, and MVIL, LLC, a wholly-owned subsidiary of Morningside. The Reporting Person is an investment professional at Morningside Technology Advisory, LLC, an indirect advisor to Morningside and MVIL, LLC and may be deemed to indirectly beneficially own the shares held by Morningside and MVIL, LLC. The Reporting Person has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of such shares. Read SEC document |
| January 06, 2022 Filed Jan 11, 2022 01:35 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionSeries A Preferred Stock · Derivative | 1,409,035 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-001525 · doc4.xml · derivative · entry 6 Cheng Isaac · CIK 0001829696 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,409,035 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1 and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1 and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1 and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date. F2 · ownership.nature: These shares are held directly by Morningside Venture Investments Limited, or Morningside, and MVIL, LLC, a wholly-owned subsidiary of Morningside. The Reporting Person is an investment professional at Morningside Technology Advisory, LLC, an indirect advisor to Morningside and MVIL, LLC and may be deemed to indirectly beneficially own the shares held by Morningside and MVIL, LLC. The Reporting Person has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of such shares. Read SEC document |
| January 06, 2022 Filed Jan 11, 2022 01:35 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | PurchaseCommon Stock | 6,578 | $19.00 | $124,982.00 |
DisclosureSEC source: 0000899243-22-001525 · doc4.xml · nonDerivative · entry 5 Cheng Isaac · CIK 0001829696 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,578 Read SEC document |
| January 06, 2022 Filed Jan 11, 2022 01:35 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionCommon Stock | 1,621,544 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-001525 · doc4.xml · nonDerivative · entry 4 Cheng Isaac · CIK 0001829696 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,415,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1 and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date. F2 · ownership.nature: These shares are held directly by Morningside Venture Investments Limited, or Morningside, and MVIL, LLC, a wholly-owned subsidiary of Morningside. The Reporting Person is an investment professional at Morningside Technology Advisory, LLC, an indirect advisor to Morningside and MVIL, LLC and may be deemed to indirectly beneficially own the shares held by Morningside and MVIL, LLC. The Reporting Person has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of such shares. Read SEC document |
| January 06, 2022 Filed Jan 11, 2022 01:35 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionCommon Stock | 974,107 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-001525 · doc4.xml · nonDerivative · entry 3 Cheng Isaac · CIK 0001829696 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,794,106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1 and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date. F2 · ownership.nature: These shares are held directly by Morningside Venture Investments Limited, or Morningside, and MVIL, LLC, a wholly-owned subsidiary of Morningside. The Reporting Person is an investment professional at Morningside Technology Advisory, LLC, an indirect advisor to Morningside and MVIL, LLC and may be deemed to indirectly beneficially own the shares held by Morningside and MVIL, LLC. The Reporting Person has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of such shares. Read SEC document |
| January 06, 2022 Filed Jan 11, 2022 01:35 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionCommon Stock | 6,410,964 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-001525 · doc4.xml · nonDerivative · entry 2 Cheng Isaac · CIK 0001829696 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,819,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1 and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date. F2 · ownership.nature: These shares are held directly by Morningside Venture Investments Limited, or Morningside, and MVIL, LLC, a wholly-owned subsidiary of Morningside. The Reporting Person is an investment professional at Morningside Technology Advisory, LLC, an indirect advisor to Morningside and MVIL, LLC and may be deemed to indirectly beneficially own the shares held by Morningside and MVIL, LLC. The Reporting Person has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of such shares. Read SEC document |
| January 06, 2022 Filed Jan 11, 2022 01:35 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionCommon Stock | 1,409,035 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-001525 · doc4.xml · nonDerivative · entry 1 Cheng Isaac · CIK 0001829696 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,409,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1 and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date. F2 · ownership.nature: These shares are held directly by Morningside Venture Investments Limited, or Morningside, and MVIL, LLC, a wholly-owned subsidiary of Morningside. The Reporting Person is an investment professional at Morningside Technology Advisory, LLC, an indirect advisor to Morningside and MVIL, LLC and may be deemed to indirectly beneficially own the shares held by Morningside and MVIL, LLC. The Reporting Person has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of such shares. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 21:39 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $24.00 | $0.00 |
DisclosureSEC source: 0000899243-20-029951 · doc4.xml · derivative · entry 1 Cheng Isaac · CIK 0001829696 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2030-10-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in 36 equal monthly installments following October 29, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.